IP Library Granted Patent US 7,947,807
Granted Patent B2
US 7,947,807 · App. 12/284,245 · Granted May 24, 2011

Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)

Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,947,807
App. No.
12/284,245
Granted
May 24, 2011
Kind
B2
Abstract

An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.

Claims (17)

1. A method for obtaining crystals of a G protein-coupled receptor (GPCR), comprising:

a) contacting said GPCR with a monovalent antibody that

i. specifically binds to a three dimensional epitope of the intracellular region 3 (IC3) loop of said GPCR and

ii. stabilizes the relative conformations of the transmembrane region 5 (TM5) and transmembrane region 6 (TM6) of said GPCR,

under conditions that provide for binding of said antibody to said GPCR produce an antibody/GPCR complex;

b) removing unbound antibody from the product of step a); and

c) maintaining the product of step b) under conditions suitable for crystallizing said antibody/GPCR complex thereby producing a crystalline form of said antibody/GPCR complex.

2. The method of claim 1 , wherein said method comprises combining said antibody/GPCR complex with lipids prior to crystallizing said complex.

3. The method of claim 1 , wherein said antibody/GPCR complex is crystallized using a bicelle crystallization method or a cubic-phase crystallization method.

4. The method of claim 1 , wherein said GPCR comprises the IC3 loop of the β2 adrenoreceptor (β2AR).

5. The method of claim 1 , wherein said GPCR is a chimeric GPCR that contains the IC3 loop of β2AR.

6. The method of claim 1 , wherein said GPCR is a chimeric GPCR that comprises amino acid residues I223 to K270 of β2AR.

7. The method of claim 6 , wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:1 and a heavy chain comprising the amino acid sequence of SEQ ID NO:2.

8. The method of claim 1 , wherein the antibody is made by:

reconsitituting a GPCR in artificial phospholipid vesicles to make an antigen;

immunizing an animal with said antigen; and

screening a plurality of hybridoma lines obtained from said animal for a hybridoma that produces said antibody.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jul 28, 2010
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024756/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2009
From: MEDAREX INC.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 022353/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2009
From: KOBILKA, BRIAN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 022292/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2009
From: ROHRER, DANIEL K.; BRAMS, PETER; MASOOD, ASNA
To: MEDAREX, INC.
Reel/Frame 022292/0232 →
CONFIRMATORY LICENSE Recorded Feb 19, 2009
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022284/0478 →
Continuity (2)
Provisional Application 60980122 · Oct 15, 2007
Related Publication 20090148510A1 · Jun 11, 2009